# Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

> **NCT01404325** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 130 (actual)

## Conditions studied

- Lung Transplantation

## Interventions

- **DRUG:** standard therapy
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01404325
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-01
- **Primary completion:** 2017-01-05
- **Final completion:** 2017-01-05
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01404325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01404325, "Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01404325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*